IDiyas

For the Inventor, By the Inventor

Vendemian, France

Jean-Laurent Paparin

USPTO Granted Patents = 14 

 

Average Co-Inventor Count = 6.7

ph-index = 4

Forward Citations = 97(Granted Patents)


Location History:

  • Montpellier, FR (2020)
  • Vendemian, FR (2011 - 2023)

Company Filing History:

goldMedal10 out of 100 
 
Idenix Pharmaceuticals, Inc.
 patents
silverMedal6 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
bronzeMedal2 out of 7 
 
Enyo Pharma
 patents
4. 1 out of 203 
 
Southern Research Institute
 patents
5. 1 out of 7 
 
Msd International Gmbh
 patents
where one patent can have more than one assignee

Years Active: 2011-2024

Loading Chart...
Loading Chart...
14 patents (USPTO):Explore Patents
1. 12173026 - PRMT5 inhibitors (2024-12-24),
2. 11767316 - Non-fused thiophene derivatives and their uses (2023-09-26),
3. 11603368 - Fused thiophene derivatives and their uses (2023-03-14),
4. 11123355 - Antiviral benzyl-amine phosphodiamide compounds (2021-09-21),
5. 10815264 - Nucleotides for the treatment of cancer (2020-10-27),
6. 10745428 - Antiviral phosphodiamide prodrugs of tenofovir (2020-08-18),
7. 10736908 - Antiviral aryl-amide phosphodiamide compounds (2020-08-11),
8. 10519159 - Antiviral aliphatic ester prodrugs of tenofovir (2019-12-31),
9. 10449208 - Antiviral prodrugs of tenofovir (2019-10-22),
10. 10202411 - 3'-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV (2019-02-12),
11. 9187496 - 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors (2015-11-17),
12. 8362068 - 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors (2013-01-29),
13. 8193372 - Phosphothiophene and phosphothiazole HCV polymerase inhibitors (2012-06-05),
14. 7932240 - Phosphadiazine HCV polymerase inhibitors IV (2011-04-26),

Title: The Innovative Contributions of Jean-Laurent Paparin

Introduction

Jean-Laurent Paparin is a notable inventor based in Vendemian, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target various diseases. With a total of 14 patents to his name, Paparin's work has the potential to impact the treatment of serious health conditions.

Latest Patents

Among his latest patents, one notable invention is related to PRMT5 inhibitors. This invention provides a compound of Formula (I) and its pharmaceutically acceptable salts, esters, and prodrugs, which serve as PRMT5 inhibitors. The patent also outlines methods for making these compounds, pharmaceutical compositions that include them, and their applications in treating cancer, sickle cell disease, and hereditary persistence of fetal hemoglobin (HPFH) mutations. Another significant patent involves non-fused thiophene derivatives and their uses. This invention introduces a new class of non-fused thiophene derivatives that can be utilized in treating various diseases, including infections, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders, and inflammatory disorders.

Career Highlights

Throughout his career, Jean-Laurent Paparin has worked with prominent companies in the pharmaceutical industry. He has been associated with Idenix Pharmaceuticals, Inc. and Merck Sharp & Dohme Corporation, where he has contributed to innovative research

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…